Gliprip-M2 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The extended-release formulation of Gliprip-M2 Forte Tablet PR allows for sustained drug release, promoting better glycemic control with potentially reduced gastrointestinal side effects compared to immediate-release formulations. This combination therapy is particularly beneficial for patients inadequately controlled on diet and exercise alone or on monotherapy with either agent. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or those at risk of lactic acidosis. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Gliprip-M2 Forte Tablet PR should be used under medical supervision with appropriate lifestyle modifications, including diet and exercise, to optimize diabetes management and minimize complications.

Dosage & How to Use